HIV-1 integrase inhibitor

CAS : 544467-07-4

Ref. 3D-FA64909

Informations sur le produit

• Nom: HIV-1 integrase inhibitor
• Synonymes: 4-[3-(Azidomethyl)phenyl]-2-hydroxy-4-oxo-2-butenoic acid

Description

Integrase inhibitors are a class of drugs that inhibit the function of integrase. They prevent HIV-1 from integrating into the host cell genome and thus arrest the progression of HIV-1 infection. There are many analytical methods that can be used to determine the presence of integrase in cells, such as transfection experiments, toxicity studies, drug interactions, and bioassays. One pharmacological agent that has been shown to inhibit integrase is raltegravir (Isentress), which is a protease inhibitor. Raltegravir is available in tablet form for oral administration. It inhibits HIV-1 replication by binding to the active site of human immunodeficiency virus type 1 (HIV-1) integrase and prevents its integration into host cell DNA. This drug has been shown to be beneficial when used in conjunction with other antiretroviral agents for treating HIV-1 infections.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 247.21 g/mol
• Formule: C₁₁H₉N₃O₄
• Degré de pureté: Min. 95%
• Couleur/Forme: Powder